Researcher
Mourad Gumusboga
- Disciplines:Bacteriology
Affiliations
- Mycobacteriology (Research unit)
Member
From1 Jan 2003 → Today - Mycobacteriology (Research unit)
Member
From1 Jan 2003 → 16 Apr 2015
Projects
1 - 2 of 2
- Novel High-Dose Tuberculosis Retreatment Regimens: How to overcome resistance without creating more?From1 Oct 2018 → 30 Sep 2024
- Institutional strengthening of the Mycobacteria Reference Laboratory (LRM, Bénin) for quality services and better quality of health care for Mycobacteria and other clinical bacteria, at National and Regional Level.From1 Jan 2018 → 31 Dec 2018
Publications
1 - 10 of 22
- Successful Mycobacterium tuberculosis culture isolation from tongue swabs: Results from both experimentally infected and clinical swabs from pulmonary tuberculosis patients(2024)
Authors: L Rigouts, M Conde, Souleymane Hassane-Harouna, K Bah, Mourad Gumusboga, M Ruhwald, Rabab Reenaers, M Gaichiri, M De Vos, Bouke de Jong
- Acquired rifampicin resistance during first TB treatment: magnitude, relative importance, risk factors and keys to control in low-income settings(2022)
Authors: Armand Van Deun, Valentin Bola, Rossin Lebeke, Michel Kayomo Kaswa, Mohamed Anwar Hossain, Mourad Gumusboga, Bouke de Jong, L Rigouts, Tom Decroo
- The simple direct slide method is comparable to indirect Lowenstein Jensen proportion culture for detecting rifampicin resistant tuberculosis(2021)
Authors: Beatrice Achan, Benon B. Asiimwe, Moses L Joloba, Mourad Gumusboga, Willy Ssengooba, Freddie Bwanga
- Finding the right balance between efficacy and tolerability for TB treatment: the search continues(2021)
Authors: A.K.J. Maug, M.A. Hossain, Mourad Gumusboga, Tom Decroo, Wim Mulders, Sofie Braet, D A Jiménez, Céline Schurmans, Natacha Herssens, T. Demeulenaere, et al.
Pages: 84-86 - Mycobacterium tuberculosis borderline rpoB mutations: emerging from the unknown(2021)
Authors: Armand Van Deun, Tom Decroo, Kya Jai Maug Aung, Mohamed Anwar Hossain, Mourad Gumusboga, Pim De Rijk, Sabira Tahseen, Bouke de Jong, L Rigouts
- Bedaquiline can act as core drug in a standardized treatment regimen for fluoroquinolone-resistant rifampicin-resistant tuberculosis(2021)
Authors: T Decroo, Kya Jai, Kya Jai Maug Aung, Mohamed Anwar Hossain, Mourad Gumusboga, Nimer Ortuno-Gutierrez, Bouke C de Jong, Armand Van Deun
- Management of multidrug-resistant tuberculosis with shorter treatment regimen in Niger: nationwide programmatic achievements(2020)
Authors: Alberto Piubello, Mahamadou Bassirou Souleymane, Souleymane Hassane-Harouna, Abdourahamane Yacouba, Mourtala Mohamed Assao-Neino, Ibrahim Maman-Lawan, Sala Attaher, Boubacar Moustapha, Alphazazi Soumana, Assiatou Gagara-Issoufou, et al.
- Injectables' key role in rifampicin-resistant tuberculosis shorter treatment regimen outcomes(2020)
Authors: Tom Decroo, Aung Kya Jai Maug, Mohamed Anwar Hossain, Cécile Uwizeye, Mourad Gumusboga, Tine Demeulenaere, Nimer Ortuno-Gutierrez, Bouke de Jong, Armand Van Deun
- First-line tuberculosis treatment with double-dose rifampicin is well tolerated(2020)
Authors: A.K.J. Maug, M.A. Hossain, Mourad Gumusboga, T Decroo, Wim Mulders, Sofie Braet, J Buyze, Diana Arango, C Schurmans, Natacha Herssens, et al.
Pages: 499-505 - Variable ability of rapid tests to detect Mycobacterium tuberculosis rpoB mutations conferring phenotypically occult rifampicin resistance(2019)
Authors: Gabriela Torrea, Kamela Charmaine Sy Ng, Armand Van Deun, Emmanuel André, Justine Kaisergruber, Willy Ssengooba, Christel Desmaretz, Siemon Gabriëls, Michèle Driesen, Maren Diels, et al.